虽然全球经济受到金融危机的巨大冲击,但生物医药产业的发展却并没有减速,尤其在甲型H1N1等公共卫生事件的蔓延下,医药行业的发展更加受到关注。在2009年国务院常务会议讨论并原则通过《促进生物产业加快发展的若干政策》后,一行三会叉将新医药列为2010年国家产业政策鼓励发展的重点,新医药产业被提到了一个崭新的高度。政策与人口效应的双重拉动 1.老龄化与城镇化推动医疗服务市场增容中国目前处在城镇化率提升、国家医改投入持续增加、居民就诊意愿加强的时期。2008年,中国总人口已经突破13.2亿,卫生总费用占GDP的比例达到4.52%。随着人口老龄化的加剧,给社会带来的一个影响就是医药费用支出比例的提高。在我国,老年人全年的人均医 Although the global economy was hit hard by the financial crisis, the development of the biomedicine industry has not slowed down. In particular, the development of the pharmaceutical industry has drawn more attention, especially under the spread of public health events such as H1N1. After the State Council executive meeting discussed and approved in principle “a number of policies to promote the accelerated development of the bioindustry industry”, a group of three leaders pointed out that new medicine should be the focus of encouragement for the development of national industrial policies in 2010. The new pharmaceutical industry was referred to a brand new height. Policy and population effects of dual pull 1. Aging and urbanization to promote medical service market capacity China is currently in the urbanization rate, the state continued to increase investment in medical reform, residents to strengthen the ambition period. In 2008, China’s total population has exceeded 1.32 billion, with the total health expenditure accounting for 4.52% of GDP. As the aging of the population increases, one impact on society is the increase in the proportion of medical expenses. In our country, the average annual per capita medical treatment of the elderly